InvestorsHub Logo

Wolf-man jack

03/05/21 12:36 PM

#71851 RE: CNIMBill #71850

Most likely further down the pipeline, no pun intended YQU Understand. Imho Have Mercy Wolf Ahooooooo


Dr. Joong J Fang Said;

FROM SEED TO SHELF™

“ Goods and Services: Protein derived from hemp for use in the manufacture of a wide variety of goods, namely, body care and toiletry products, dietary and nutritional supplements, nutritional food additive for culinary purposes, beverages and food stuffs and clothing”

https://trademark.trademarkia.com/from-seed-to-shelf-86521967.html

WOLFMAN JACK SAID ;



motorcity

03/05/21 2:24 PM

#71852 RE: CNIMBill #71850

I think where CVSI went wrong in hindsight was preparing for an fda regulated world that unfortunately hasn't come, yet.

Assuming the FDA does regulate the requirements for an infused food or beverage are far higher than a dietary supplement, in large part because it's near impossible to regulate dosage.

IMO CVSI has stayed away from this because they don't see a path to federal legality. And state level legality is leaving the door open for charletans and making federal banking impossible.

I also believe cvsi intentionally stayed away from online sales expecting it would give them a better chance with retailers once cbd went federally legal, again because they expected this 2-3 years ago.

Freedom43

03/05/21 4:15 PM

#71853 RE: CNIMBill #71850

I would add, call it a mistake or prudence. CVSI has been extremely conservative in just about every aspect. Playing it by the book.

Here's some of the things I appreciate as a long:

Staying clear convertible debt to maintain control of outstanding shares
Achieving GRAS (Toxicology)
Maintaining adverse events reporting
Adding a solid advisory board
Adding experienced management, sales and regulatory personnel
Adding new Non-CBD immunity products in advance of the competition - Started in Dec 2019

It's just disappointing the FDA won't clear the path to national distribution for companies doing business the RIGHT WAY.

Hopefully we'll be hearing more on the drug development as FDA claims to be open in that facet.